CAR-T 2020 | Cytopenia in CART — the prolonged threat of infection

Marion Subklewe, from the Ludwig Maximilian University of Munich, DE, discussed cytopenia in patients who received CAR T-cell therapy...

CAR T-cell approaches for the treatment of patients with B- and T-cell lymphomas

During the 2nd CAR T meeting, Martin Pule from University College London, presented an overview of the CAR T-cell...

Third-generation CAR-CD30 T-cell therapy for CD30-positive lymphomas

Preclinical advances of a third-generation, anti-CD30 CAR T-cell therapy were presented by Biagio De Angelis, Bambino Gesù...

Implementation of CAR T-cell therapy in the real world - A round table discussion

The Lymphoma Hub is pleased to report a summary of real-world experiences of chimeric antigen receptor (CAR) T-cell...

Phase I study of oral 5-azacytidine and romidepsin in patients with PTCL

This phase I trial assessed the effect of AZA plus ROMI in the treatment of relapsed or refractory (R/R) non-Hodgkin lymphoma...

Nanatinostat plus valganciclovir granted Fast Track designation by the FDA for the treatment of patients with EBV-associated lymphomas

Nanatinostat plus valganciclovir granted Fast Track designation...

Abexinostat granted FDA's Fast Track designation for the treatment of patients with relapsed or refractory follicular lymphoma

The FDA has granted abexinostat Fast Track designation as a fourth-line...

SOHO 2019 | What is in the pipeline for the treatment of T-cell lymphoma?

At SOHO 2019, Dr Owen A. O'Connor updated us on treatments in the pipeline for T-cell lymphoma and recent clinical...

Nanatinostat plus valganciclovir granted Fast Track designation by the FDA for the treatment of patients with EBV-associated lymphomas

Nanatinostat plus valganciclovir granted Fast Track designation...

Population-based study: Association of secondary primary malignancies and DLBCL stage at diagnosis

Population-based study: Association of secondary primary malignancies and DLBCL stage at diagnosis

Dose-adjusted EPOCH with or without rituximab for NHL-associated HLH: Results from a phase II trial

this single-arm, open-label study the efficacy and safety of dose-adjusted EPOCH with or without...

ASH 2018 | Real-world efficacy and safety outcomes with axi-cel in patients with relapsed/refractory large B-cell lymphoma comparable to the ZUMA-1 clinical trial

The study evaluated the real-world...